natgillin/translations-raw huggingface dataset:
Afamelanotide is a synthetic tridecapeptide and a structural analogue of α-melanocyte stimulating hormone (α-MSH).
Afamelanotid je sintetski tridekapeptid i strukturalni analog α-melanocit stimulirajućeg hormona
Instruction for use
15. UPUTE ZA UPORABU
Type I amber glass vial sealed with a PTFE coated rubber stopper.
I zatvorena gumenim čepom obloženim PTFE-om.
- Hold the catheter at its base using a sterile technique, pinch and hold the skinfold cranial to, or overlying the patient's supra-iliac crest with two fingers.
- Sterilnom tehnikom primite kateter u bazi katetera, te s dva prsta uštipnite i držite nabor kože na mjestu koje je iznad ili prekriva bolesnikov ilijačni greben.
Afamelanotide may induce darkening of pre-existing pigmentary lesions due to its pharmacological effect.
Uslijed farmakološkog djelovanja, afamelanotid može uzrokovati tamnjenje prethodno postojećih pigmentacijskih lezija.
Haematoma Diastolic hypertension Hypertension
dijastolička hipertenzija,
- Wound complication, open wound
krv u urinu - Komplikacije rana, otvorena rana
• Demonstration of the correct application technique, highlighting the measures needed to ensure the implant is not damaged during use.
Materijal za individualnu obuku, uključujući edukacijski video, obuhvaća sljedeće ključne poruke: • demonstraciju ispravne tehnike primjene, naglašavajući mjere potrebne kako bi se osiguralo da se implantat ne ošteti tijekom uporabe.
Disease registry
Registar bolesti
Women of childbearing potential have to use effective contraception during treatment with SCENESSE and for a period of three months thereafter.
Žene reproduktivne dobi moraju koristiti učinkovitu kontracepciju tijekom liječenja lijekom
Pre- and post-natal development of Sprague-Dawley rats was not affected at exposures of about 135-times the human exposure (based on Cmax).
Sprague-Dawley štakora pri otprilike 135 puta većoj izloženosti od izloženosti u ljudi (na temelju
- Cushing's disease (a hormone disorder where the body produces too much of the hormone cortisol); - Addison's disease (a disorder of the adrenal glands causing a lack of some hormones); - Peutz-Jeghers syndrome (a disorder that causes blockage of the bowel and where your hands, soles of your feet and surface of your lips may have brown freckles); - epilepsy (or have been told that you are at risk of having fits); - anaemia (low counts of red blood cells in your blood); - melanoma (an aggressive type of skin cancer), including in-situ melanoma, e.g. lentigo maligna; or if you have certain inherited conditions that increase the risk of developing a melanoma; - skin cancer of the types, basal cell carcinoma or squamous cell carcinoma (inclusive of carcinoma in situ, e.g. Bowen's disease), Merkel cell carcinoma or other malignant or premalignant skin problems.
- anemiju (nizak broj crvenih krvnih stanica u krvi). - melanom (agresivan tip raka kože), uključujući melanom in situ, primjerice lentigo maligna; ili ako imate određena nasljednja stanja koja povećavaju rizik od razvoja melanoma. - rak kože sljedećih tipova: karcinom bazalnih stanica ili karcinom pločastih stanica (uključujući karcinom in situ, primjerice Bowenovu bolest), karcinom Merkelovih stanica ili drugi maligni ili predmaligni problemi kože.
- Apply a small pressure dressing to the injection site.
- Na ubodno mjesto primijenite mali kompresivni zavoj.
- Remove the needle from within the catheter using a sterile technique.
- Primjenom sterilne tehnike izvadite iglu iz unutrašnjosti katetera.
- Joint pain, muscle pain, pain in arms and legs, sudden muscle contraction, pain in muscles and bones, stiffness of muscles and bones, joint stiffness, groin pain, feeling of heaviness, swelling in lower limbs
- Bol u zglobovima, mišićna bol, bol u rukama i nogama, iznenadne mišićne kontrakcije, bol u mišićima i kostima, ukočenost mišića i kosti, ukočenost zglobova, bol u preponama, osjećaj težine, oticanje donjih udova
Over time the implant will be absorbed by the body, this will happen within 50 to 60 days after implantation.
To će se dogoditi 50 do 60 dana nakon ugradnje.
- Pain, swelling around site of implantation, bruising at injection site, irritation at injection site, enlargement at implant site, itching at implant site, implant falling out, change in colour of skin at implant site
- Bol, oticanje oko mjesta ugradnje implantata, modrice na mjestu injekcije, nadraženost na mjestu injekcije, povećanje na mjestu implantata, svrbež na mjestu implantata, ispadanje implantata, promjena boje kože na mjestu implantata
Eumelanin contributes to photoprotection through different mechanisms including: - strong broadband absorption of UV and visible light, where eumelanin acts as a filter - antioxidant activity through scavenging of free radicals; and - inactivation of the superoxide anion and increased availability of superoxide dismutase to reduce oxidative stress.
Eumelanin doprinosi fotozaštiti putem različitih mehanizama uključujući: - snažnu širokopojasnu apsorpciju UV i vidljivog svjetla, pri čemu eumelanin djeluje kao filtar
The two total full body skin examinations per year are intended to: - detect early any skin cancers and their precursors induced by UV-exposure, as EPP patients can be expected to significantly increase their exposure to sunlight and UV light while on treatment with afamelanotide.
Dva pregleda kože cijeloga tijela godišnje namijenjena su: - ranom otkrivanju svih vrsta raka kože i njegovih prekursora uzrokovanih izlaganjem UV
Haemangioma
hemangiom
There are no or limited amounts of data from the use of afamelanotide in pregnant women.
Nema podataka ili su podaci o primjeni afamelanotida u trudnica ograničeni.
- Confirm insertion of the implant by palpating the skin with subcutis cranial to/overlying the suprailiac crest until the implant is located.
- Palpacijom kože potvrdite umetanje implantata u potkožno tkivo na mjestu koje je iznad ili prekriva ilijačni greben sve dok ne locirate implantat.
Back pain
- bol u leđima
Abdominal pain Abdominal pain upper Diarrhoea
Mučnina bol u abdomenu bol u gornjem dijelu abdomena Proljev
- Increased hunger, nausea following implant insertion, indigestion, infection in stomach and intestines, inflamed stomach and intestines, heartburn, inflamed stomach, irregular bowel movements, wind, bloated tummy, tummy pain
- Povećana glad, mučnina nakon umetanja implantata, probavne tegobe, infekcija u želucu i crijevima, upaljen želudac i crijeva, žgaravica, upaljen želudac, neredovito pražnjenje crijeva, vjetrovi, napuhnut trbuh, bol u trbuhu
Due to limited data in treatment of elderly patients, the use of afamelanotide is not recommended (see section 4.4).
Zbog ograničenih podataka o liječenju starijih bolesnika, primjena afamelanotida se ne preporučuje
Liver function test abnormal Transaminases increased Transferrin saturation decreased
poremećene vrijednosti testa jetrene funkcije, povišene transaminaze,
Blood cholesterol increased Blood glucose increased Blood iron decreased Blood pressure diastolic increased
povišen kolesterol, povišene razine šećera, smanjene razine željeza u krvi, povišen krvni tlak,
- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 - Presence of severe hepatic disease - Hepatic impairment (see section 5.2) - Renal impairment (see section 5.2)
- Oštećenje funkcije jetre (vidjeti dio 5.2) - Oštećenje funkcije bubrega (vidjeti dio 5.2)
Upper respiratory tract infection
- infekcije gornjih dišnih putova (prehlade).
- Depression, inability to sleep, poor quality sleep, fainting, fainting sensation, fall, hangover, weakness, inability to get legs comfortable, increased sensitivity to touch, headache following injury, burning sensation, abnormal taste sensation
- Depresija, nesanica, slaba kvaliteta sna, nesvjestica, osjećaj nesvjestice, padanje, mamurnost, slabost, nekontrolirani poriv za pokretanje nogu zbog neugodnog osjećaja u nogama, povećana osjetljivost na dodir, glavobolja nakon ozljede, osjećaj žarenja, nenormalan osjet okusa - Nateknuti očni kapci, crvene oči, suho oko, poteškoće s fokusiranjem na predmete koji su blizu,
AUTHORISATION
Efelidi
- Heavy and prolonged period, abnormal period, breast tenderness, irregular periods, discharge from vagina, decreased sex drive
- Obilna i produljena mjesečnica, nenormalna mjesečnica, osjetljivost dojki, neredovite mjesečnice, iscjedak iz rodnice, smanjeni seksualni nagon
How SCENESSE is stored
Kako se primjenjuje SCENESSE
Melanocytic naevus Pigmentation disorder Skin discolouration Skin hyperpigmentation Ephelides
Poremećaj pigmentacije Promjena boje kože Hiperpigmentacija kože
METHOD AND ROUTE(S) OF ADMINISTRATION Read the package leaflet before use Subcutaneous use
NAČIN I PUT(EVI) PRIMJENE LIJEKA Prije uporabe pročitajte uputu o lijeku.
synonyms: familial atypical mole-malignant melanoma syndrome, FAMMM; dysplastic naevus syndrome, DNS; B-K mole syndrome; CMM2 MIM #155601) and/or an - individual history of basal cell carcinoma, squamous cell carcinoma (inclusive of carcinoma in situ, e.g. Bowen's disease), Merkel cell carcinoma, or other malignant or premalignant skin lesions.
MIM #155600, sinonimi: obiteljski sindrom atipičnog madeža-malignog melanoma, FAMMM; sindrom displastičnih nevusa, DNS; sindrom B-K madeža; CMM2 MIM #155601)
- Chills, fever, flu, flu-like illness, blocked nose, blocked sinuses, inflamed nose and throat, nose inflammation
- Inficirani folikuli kose, gljivična infekcija, infekcija mokraćnog sustava - Zimice, vrućica, gripa, bolest nalik gripi, začepljen nos, začepljeni sinusi, upaljen nos i grlo,
Procedural nausea
mučnina tijekom postupka,
• Summary of product characteristics,
• sažetak opisa svojstava lijeka,
NAME OF THE MEDICINAL PRODUCT SCENESSE 16 mg implant
NAZIV LIJEKA SCENESSE 16 mg implantat
No clinical data are available on the use of afamelanotide in breastfeeding women.
Nema dostupnih kliničkih podataka o primjeni afamelanotida u dojilja.
- Inflamed lips, lip swelling, colouration on lip, gum pain, toothache, discoloured gums, reduced sense of touch in mouth, lip discolouration, tongue discolouration
- Upaljene usnice, oticanje usnica, obojanost usnice, bol u zubnom mesu, zubobolja, promjena boje zubnog mesa, smanjeni osjet dodira u ustima, promjena boje usnice, promjena boje jezika
- The active substance is afamelanotide.
Što SCENESSE sadrži - Djelatna tvar je afamelanotid.
Aspartate aminotransferase increased
Povišena razina kreatin fosfokinaze u krvi povišena alaninaminotransferaza, povišena aspartataminotransferaza,
Flushing Hot flush
- navale vrućine
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION SCENESSE 16 mg implant afamelanotide
NAZIV LIJEKA I PUT(EVI) PRIMJENE LIJEKA SCENESSE 16 mg implantat afamelanotid
SCENESSE 16 mg implant afamelanotide
NAZIV LIJEKA SCENESSE 16 mg implantat afamelanotid
Gingival discolouration
Tablični prikaz nuspojava
Blood urine present Biopsy skin
povišen dijastolički krvni tlak, prisutnost krvi u urinu, biopsija kože,
- Mark 1.5 to 2 cm on the catheter shaft using surgical ink.
- Na trupu katetera označite kirurškom tintom 1,5 do 2 cm.
If you suffer from continued drowsiness, then you should speak to your doctor.
Ako omamljenost ne prestaje, obratite se svom liječniku.
Eye disorders
zujanje u ušima
Injury, poisoning and procedural complications
Ozljede, trovanja i proceduralne komplikacije komplikacija rane, otvorena rana, pad,
Gastroesophageal reflux disease
Retrospektivno ispitivanje s pregledom kartona bolesnika
Lip oedema
RMP-a.
Myalgia
mijalgija,
Palpitations Tachycardia
Srčani poremećaji palpitacije, tahikardija,
- Irregularity of skin, rash with small blisters, itch, rash, red rash, red swelling on skin, rash with small bumps, itchy rash, skin irritation, lighter skin patches, acne, eczema, secretions on skin, skin peeling, skin with loss of colour, hair colour changes, excessive sweating
akne, ekcemi, sekrecije na koži, guljenje kože, koža s gubitkom boje, promjene u boji kose, prekomjerno znojenje
Uncommon unspecified (incl cysts and polyps) Blood and lymphatic system disorders
Poremećaji krvi i limfnog sustava leukopenija
Menorrhagia Dysmenorrhoea Breast tenderness Menstruation irregular Vaginal discharge Libido decreased
Poremećaji reproduktivnog sustava i dojki menoragija, dismenoreja, osjetljivost dojki, neredovite menstruacije, vaginalni iscjedak, smanjeni libido,
STATEMENT OF ACTIVE SUBSTANCE(S) Each implant contains 16 mg afamelanotide.
Svaki implantat sadrži 16 mg afamelanotida.
Eyelid oedema Ocular hyperaemia Dry eye
okularna hiperemija, suho oko, prezbiopija,
- decreased appetite; - fatigue (tiredness), - dizziness, drowsiness and weakness; - hot flushes; - upper respiratory tract infections (colds).
- iscrpljenost (umor) - omaglica, omamljenost i slabost
Lip swelling
(α-MSH).
Pain in extremity Muscle spasm Musculoskeletal pain Musculoskeletal stiffness Joint stiffness Groin pain
mišićno-koštana ukočenost, ukočenost zglobova,
- Decrease white blood cells, abnormal liver function tests, decreased iron binding, increased cholesterol, increased sugar level, decreased blood iron level, increased blood pressure, blood in urine
- Smanjenje broja bijelih krvnih stanica, abnormalan test funkcije jetre, smanjeno vezanje željeza,
Neoplasms benign, malignant and
san slabe kvalitete, disgeuzija,
Cardiac disorders
Krvožilni poremećaji
Nausea
- mučnina
Injection site haematoma Injection site irritation
Hematom na mjestu implantata
NAME OF THE MEDICINAL PRODUCT SCENESSE 16 mg implant afamelanotide
Uputa o lijeku: Informacije za bolesnika SCENESSE 16 mg implantat afamelanotid
Infections and infestations
- proljev i povraćanje
- Infected hair follicle, fungal infection, urinary tract infection
Infekcije i infestacije infekcija gornjih dišnih putova influenca, gastrointestinalna infekcija, gastroenteritis, folikulitis, kandidijaza, nazofaringitis,
The recommended dose is one tablet a day.
Preporučena je doza jedna tableta na dan.
Further information on Biktarvy can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Više informacija o lijeku Biktarvy možete naći na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
What measures are being taken to ensure the safe and effective use of Biktarvy?
Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Biktarvy?
What is Biktarvy and what is it used for?
Što je Biktarvy i za što se koristi?
What are the risks associated with Biktarvy?
Koji su rizici povezani s lijekom Biktarvy?
Other information about Biktarvy
Ostale informacije o lijeku Biktarvy
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Biktarvy have been included in the summary of product characteristics and the package leaflet.
Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Biktarvy nalaze se u sažetku opisa svojstava lijeka i u uputi o lijeku.
Side effects reported with Biktarvy are carefully evaluated and any necessary action taken to protect patients.
Nuspojave prijavljene za lijek Biktarvy pažljivo se procjenjuju i poduzimaju se potrebne mjere za zaštitu bolesnika.
Why is Biktarvy authorised in the EU?
Zašto je lijek Biktarvy odobren u EU-u?
Side effects were similar to those of medicines of the same class.
Nuspojave su slične nuspojavama drugih lijekova iz iste skupine.
Biktarvy (bictegravir / emtricitabine / tenofovir alafenamide)
Biktarvy (biktegravir/emtricitabin/tenofoviralafenamid)
It is only used in patients where the virus has not developed resistance to a class of HIV medicines called integrase inhibitors, or to tenofovir or emtricitabine.
Primjenjuje se samo u bolesnika u kojih virus nije razvio rezistenciju na skupinu lijekova za liječenje HIV-a koji se nazivaju inhibitori integraze, ili na tenofovir ili emtricitabin.
The European Medicines Agency therefore decided that Biktarvy's benefits are greater than its risks and it can be authorised for use in the EU.
Europska agencija za lijekove stoga je zaključila da koristi lijeka Biktarvy nadmašuju s njim povezane rizike te da lijek može biti odobren za primjenu u Europskoj uniji.
For more information about using Biktarvy, see the package leaflet or contact your doctor or pharmacist.
Za više informacija o primjeni lijeka Biktarvy pogledajte uputu o lijeku ili se obratite liječniku ili ljekarniku.
Biktarvy was shown to be as effective as comparator antiviral medicines.
Lijek Biktarvy pokazao se jednako učinkovitim kao i usporedni antivirusni lijekovi.
As for all medicines, data on the use of Biktarvy are continuously monitored.
Kao za sve lijekove, podaci o primjeni lijeka Biktarvy kontinuirano se prate.
Biktarvy contains three active substances which work in different ways against HIV:
Biktarvy sadrži tri djelatne tvari koje djeluju protiv HIV-a na različite načine:
It blocks an enzyme called integrase that is needed by the HIV virus to make new copies of itself in the body.
On inhibira enzim naziva integraza koji je virusu HIV-a potreban da stvori nove kopije samoga sebe u tijelu.
The most common side effects with Biktarvy (which may affect around 1 in 20 people) are headache, diarrhoea and nausea (feeling sick).
Najčešće nuspojave lijeka Biktarvy (koje se mogu javiti u otprilike 1 na 20 osoba) su glavobolja, proljev i mučnina (osjećaj slabosti).
The benefits of Biktarvy in the treatment of HIV infection were investigated in four main studies.
Koristi lijeka Biktarvy u liječenju infekcije HIV-om istraživane su u okviru četiriju glavnih ispitivanja.
Biktarvy is an antiviral medicine used to treat adults infected with human immunodeficiency virus 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
Biktarvy je antivirusni lijek koji se primjenjuje za liječenje odraslih osoba zaraženih virusom humane imunodeficijencije tipa 1 (HIV-1), virusom koji uzrokuje sindrom stečene imunodeficijencije (AIDS).
An overview of Biktarvy and why it is authorised in the EU
Pregled informacija o lijeku Biktarvy i zašto je odobren u EU-u
Tenofovir is a nucleotide reverse transcriptase inhibitor (NRTI), which means that it blocks the activity of reverse transcriptase, another enzyme of the virus that allows it to reproduce itself.
Tenofovir je nukleotidni inhibitor reverzne transkriptaze (NRTI), što znači da blokira djelovanje reverzne transkriptaze, još jednog enzima virusa koji virusu omogućuje množenje.
• Bictegravir is a type of antiviral agent called an ‘integrase inhibitor'.
• Biktegravir je vrsta antivirusne tvari koja se naziva „inhibitor integraze”.
Biktarvy does not cure HIV-1 infection or AIDS, but it can hold off damage to the immune system and the development of infections and diseases associated with AIDS.
Biktarvy ne može izliječiti infekciju HIV-om ili AIDS, ali može privremeno zaustaviti narušavanje imunosnog sustava i razvoj infekcija i bolesti povezanih s AIDS-om.
Biktarvy is available as tablets, each containing 50 mg bictegravir, 200 mg emtricitabine, and 25 mg tenofovir alafenamide.
Lijek Biktarvy dostupan je u obliku tableta koje sadrže 50 mg biktegravira, 200 mg emtricitabina i 25 mg tenofoviralafenamida.
• Emtricitabine is another type of NRTI (a nucleoside reverse transcriptase inhibitor) and it works in the same way as tenofovir.
• Emtricitabin je druga vrsta NRTI-ja (nukleotidni inhibitor reverzne transkriptaze) i djeluje na isti način kao i tenofovir.
Two studies involved adults infected with HIV-1 who had not been treated previously, and looked at the numbers whose viral load (the amount of HIV-1 in the blood) was reduced to less than 50 copies per ml after 48 weeks of treatment.
Dva ispitivanja obuhvatila su odrasle osobe zaražene virusom HIV-1 koje prethodno nisu bile liječene, a promatrao se broj bolesnika u kojih se virusno opterećenje (količina virusa HIV-1 u krvi) smanjilo na manje od 50 kopija/ml nakon 48 tjedana liječenja.
Overall, 92% of patients taking Biktarvy (290 out of 314) achieved viral load reduction, compared with 93% (293 out of 315) of patients who achieved it with the comparator.
Ukupno gledano, 92 % bolesnika koji su primali lijek Biktarvy (290 od 314) postiglo je smanjenje virusnog opterećenja, u usporedbi s 93 % (293 od 315) bolesnika koji su to postigli s usporednim lijekom.
Biktarvy can only be obtained with a prescription and treatment should be started by a doctor who has experience in the management of HIV infection.
Biktarvy se izdaje samo na liječnički recept, a liječenje mora započeti liječnik s iskustvom u liječenju infekcije HIV-om.
Biktarvy must not be used together with rifampicin (an antibiotic) or with St. John's wort (a herbal medicine used for treating depression).
Biktarvy se ne smije koristiti zajedno s rifampicinom (antibiotik) ili gospinom travom (biljni pripravak za liječenje depresije).
Two other studies involved previously treated patients in whom the viral load was already lower than 50 copies per ml, and looked at whether it increased above this level 48 weeks after patients were switched from their previous HIV treatment to Biktarvy.
U drugim dvama ispitivanjima na prethodno liječenim bolesnicima u kojih je početno virusno opterećenje bilo manje od 50 kopija/ml proučavano je je li se ono povećalo iznad te razine 48 tjedana nakon što su bolesnici prebačeni sa svoje prethodne terapije za liječenje HIV-a na lijek Biktarvy.
In the second study, the viral load went above the threshold in 2% (5 out of 290) of patients switched to Biktarvy, and in 2% (5 out of 287) of patients who stayed on their previous treatment (‘boosted' atazanavir or darunavir plus either emtricitabine/tenofovir or abacavir/lamivudine).
U drugom ispitivanju premašen je prag vrijednosti virusnog opterećenja u 2 % (5 od 290) bolesnika prebačenih na lijek Biktarvy, te u 2 % (5 od 287) bolesnika koji su nastavili s prethodnom terapijom (atazanavir ili darunavir pojačani emtricitabinom i tenofovirom ili abakavirom i lamivudinom).
What benefits of Biktarvy have been shown in studies?
Koje su koristi lijeka Biktarvy dokazane u ispitivanjima?
In one study, the percentage of patients with viral load greater than or equal to 50 copies/ml was 1% (3 out of 282) of patients who switched to Biktarvy, compared with 0.5% (1 out of 281) of patients who stayed on their previous treatment (dolutegravir, abacavir, lamivudine).
U jednom ispitivanju udio bolesnika u kojih je vrijednost virusnog opterećenja bila veća od ili jednaka 50 kopija/ml iznosio je 1 % (3 od 282) bolesnika prebačenih na lijek Biktarvy, u usporedbi s 0,5 % (1 od 281) bolesnika koji su nastavili s prethodnom terapijom (dolutegravir, abakavir, lamivudin).
How is Biktarvy used?
Kako se Biktarvy koristi?
The second study compared Biktarvy with dolutegravir plus emtricitabine/tenofovir alafenamide in 645 patients: 89% (286 out of 320) of patients taking Biktarvy achieved satisfactory viral load reduction, compared with 93% (302 out of 325) of patients on the comparator.
U drugom ispitivanju na 645 bolesnika, lijek Biktarvy uspoređen je s dolutegravirom u kombinaciji s emtricitabinom i tenofoviralafenamidom: 89 % (286 od 320) bolesnika koji su primali Biktarvy postiglo je zadovoljavajuće smanjenje virusnog opterećenja, u usporedbi s 93 % (302 od 325) bolesnika koji su primali usporedni lijek.
In the first study, Biktarvy was compared with another antiviral medicine containing abacavir, dolutegravir and lamivudine in 629 patients.
U prvom ispitivanju na 629 bolesnika, lijek Biktarvy uspoređen je s drugim antivirusnim lijekom koji je sadržavao abakavir, dolutegravir i lamivudin.
How does Biktarvy work?
Kako djeluje Biktarvy?
Biktarvy contains the active substances bictegravir, emtricitabine and tenofovir alafenamide.
Biktarvy sadrži djelatne tvari biktegravir, emtricitabin i tenofoviralafenamid.
For the full list of side effects of Biktarvy, see the package leaflet.
Potpuni popis nuspojava pri primjeni lijeka Biktarvy potražite u uputi o lijeku.
Pregnancy rate 0.9% 1.3% 1.4% 6.4% 5.7%
Broj trudnoća Stopa trudnoća 0,9% 1,3% 1,4% 6,4% 5,7%
When should emergency contraception be used?
Kada se koristi hitna kontracepcija?